# US 2021/0060089 A1 · Methods for detecting risk of having a bloodstream infection and compositions for reducing the risk

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0060089 A1
- Document ID: US20210060089A1
- Status: Published application
- Kind: A1
- Application number: 16/937,210
- Filed: 2020-07-23
- Published: 2021-03-04
- Earliest claimed: 2015-06-09
- Applicants: Regents of the University of Minnesota; Centre Hospitalier Universitaire De Nantes
- Inventors: Dan Knights; Emmanuel Montassier
- Web page: https://patentgrep.com/patent/US20210060089A1

## CPC

- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61P 31/04: Antibacterial agents
- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- C12Q 1/689: for bacteria
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Provided herein is a method for determining the relative abundance of total bacterial in a sample. Optionally, the method also includes determining whether the subject has a risk of bloodstream infection after chemotherapy, such as a chemotherapy used to prepare a subject for a hematopoietic stem cell transplantation procedure. The method includes determining the relative abundances of bacteria that are described herein as correlating with developing a bloodstream infection after chemotherapy, and determining the relative abundances of bacteria that are described herein as correlating with not developing a bloodstream infection after chemotherapy. Also provided is a composition including a mixture of isolated bacteria and a pharmaceutically acceptable carrier, where the bacteria correlate with not developing a bloodstream infection after chemotherapy. Further provided is a method for preventing a bloodstream infection in a subject by administering to a subject a composition that includes at least one type of bacteria that correlates with not developing a bloodstream infection after chemotherapy.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A method for preventing a bloodstream infection in a subject, the method comprising:
administering to a subject in need thereof a composition comprising an effective amount of at least one isolated bacteria under conditions suitable for the isolated bacteria to populate the subject's gastrointestinal tract, wherein the risk that the subject will have a bloodstream infection is reduced.

### Claim 24 (depends on 23)

The method of claim 23 wherein the isolated bacteria is selected from a member of the order RF39 in the class Mollicutes, a member of the order Clostridiales, a member of family Barnesiellaceae, a member of family Coriobacteriaceae, a member of family Rikenellaceae, a member of genus Butyricimonas, a member of genus Faecalibacterium, such as Faecalibacterium prausnitzii, a member of genus Oscillospira, a member of family Christensenella such as genus Christensenella, a member of genus Dehalobacterium, a member of genus Desulfovibrio, a member of genus Sutterella, a member of genus Methanobrevibacter, and a member of genus Oxalobacter.

### Claim 25 (depends on 23)

The method of claim 23 wherein populations of at least two isolated bacteria, at least three isolated bacteria, at least four isolated bacteria, at least five isolated bacteria, at least six isolated bacteria, at least seven isolated bacteria, at least eight isolated bacteria, at least nine isolated bacteria, at least ten isolated bacteria, at least eleven isolated bacteria, at least twelve isolated bacteria, or at least thirteen isolated bacteria are administered.

### Claim 26 (depends on 23)

The method of claim 23 wherein the subject is expected to receive chemotherapy.

### Claim 27 (depends on 23)

The method of claim 23 wherein the chemotherapy is administered before the subject undergoes a hematopoietic stem cell transplant.

### Claim 28 (depends on 23)

The method of claim 23 wherein a subject with a bloodstream risk index score that is greater than a threshold is at higher risk of a blood stream infection after undergoing chemotherapy.

### Claim 29 (depends on 28)

The method of claim 28 wherein the threshold is between −1 and 1 is at higher risk of a blood stream infection after undergoing chemotherapy.

### Claim 30 (depends on 23)

The method of claim 23 wherein the administering comprises more than one administration.

### Claim 31 (depends on 23)

The method of claim 23 wherein the administering is selected from rectal, intubation through nose or mouth, and oral.

### Claim 32 (depends on 23)

The method of claim 23 wherein the administering comprises administering at least 1×103 of each isolated bacteria.

### Claim 33 (depends on 23)

The method of claim 23 wherein the administering occurs at least 2 days before the subject undergoes the chemotherapy.

### Claim 34 (depends on 23)

The method of claim 23 wherein the isolated bacteria populate the subject's gastrointestinal tract for at least 1 day after the administration.

### Claim 35

A method for modifying the microbial population of a subject's gastrointestinal tract, the method comprising:
administering to a subject at risk of developing a bloodstream infection a composition comprising an effective amount of at least one isolated bacteria under conditions suitable for the isolated bacteria to populate the subject's gastrointestinal tract, wherein the isolated bacteria is selected from a member of the order RF39 in the class Mollicutes, a member of the order Clostridiales, a member of family Barnesiellaceae, a member of family Coriobacteriaceae, a member of family Rikenellaceae, a member of genus Butyricimonas, a member of genus Faecalibacterium, a member of genus Oscillospira, a member of family Christensenellaceae, a member of genus Dehalobacterium, a member of genus Desulfovibrio, a member of genus Sutterella, a member of genus Methanobrevibacter, and a member of genus Oxalobacter.

### Claim 36

A method for increasing the amount of bacteria in the gastrointestinal tract of a subject, the method comprising:
administering to a subject a composition comprising an effective amount of at least one isolated bacteria under conditions suitable for the isolated bacteria to populate the subject's gastrointestinal tract, wherein the amount of the at least one isolated bacteria in the subject's gastrointestinal tract is increased compared to the amount of the at least one isolated bacteria before the administering, wherein the isolated bacteria is selected from a member of the order RF39 in the class Mollicutes, a member of the order Clostridiales, a member of family Barnesiellaceae, a member of family Coriobacteriaceae, a member of family Rikenellaceae, a member of genus Butyricimonas, a member of genus Faecalibacterium, such as Faecalibacterium prausnitzii, a member of genus Oscillospira, a member of family Christensenellaceae such as genus Christensenella, a member of genus Dehalobacterium, a member of genus Desulfovibrio, a member of genus Sutterella, a member of genus Methanobrevibacter, and a member of genus Oxalobacter.

### Claim 37 (depends on 35)

The method of claim 35 wherein the subject will undergo transplantation that includes a preliminary chemotherapy step.

### Claim 38 (depends on 37)

The method of claim 37 wherein the transplantation comprises a hematopoietic stem cell transplantation.

### Claim 39 (depends on 35)

The method of claim 35 wherein the subject has a hematological malignancy.

### Claim 40 (depends on 39)

The method of claim 39 wherein the hematological malignancy, is selected from non-Hodgkin's lymphoma, myeloma, acute lymphocytic leukemia, and acute myelogenous leukemia.

### Claim 41 (depends on 35)

The method of claim 35 wherein the subject is immunocompromised.
